Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is Gardasil’s outlook in China, and while it was hoping that the company’s infant RSV antibody would pivot focus, the full results did little to alleviate concerns. Wolfe added that it would argue Merck is further clouded by competitive overhangs for its pneumococcal vaccine franchise given the ongoing nuclear arms race to increase serotype coverage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck initiated with a Peer Perform at Wolfe Research
- PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners
- Merck enters exclusive global license for LM-299
- Zentalis appoints Eastland as CEO, Bruns as CMO, Myers as Chairperson
- Ginkgo Bioworks receives $9M milestone payment from Merck partnership